top of page

Xenon's CEO on Kv7 potassium channel modulation in the CNS space and his thoughts on NaV1.7/1.8 for pain

Ian Mortimer gives the rationale for Kv7 in epilepsy and major depressive disorder, and explains why Xenon has chosen the NaV1.7 sodium channel in the pain space.





Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page